Suggested application of HER2+ breast tumor phenotype for germline TP53 variant classification within ACMG/AMP guidelines
Sign Up to like & getrecommendations! Published in 2020 at "Human Mutation"
DOI: 10.1002/humu.24060
Abstract: Early onset breast cancer is the most common malignancy in women with Li‐Fraumeni syndrome, caused by germline TP53 pathogenic variants. It has repeatedly been suggested that breast tumors from TP53 carriers are more likely to… read more here.
Keywords: her2 breast; breast; breast tumor; pathology ... See more keywords
TTK promotes HER2 + breast cancer cell migration, apoptosis, and resistance to targeted therapy by modulating the Akt/mTOR axis
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Cancer Research and Clinical Oncology"
DOI: 10.1007/s00432-024-06021-9
Abstract: HER2 + breast cancer is a malignant neoplasm with a high degree of aggressiveness and therapeutic challenge. In recent years, studies have indicated a strong correlation between TTK and various tumors, though its role in HER2 + BRCA remains… read more here.
Keywords: her2 breast; her2; ttk; breast cancer ... See more keywords
GPCRs profiling and identification of GPR110 as a potential new target in HER2+ breast cancer
Sign Up to like & getrecommendations! Published in 2018 at "Breast Cancer Research and Treatment"
DOI: 10.1007/s10549-018-4751-9
Abstract: PurposeG protein-coupled receptors (GPCRs) represent the largest family of druggable targets in human genome. Although several GPCRs can cross-talk with the human epidermal growth factor receptors (HERs), the expression and function of most GPCRs remain… read more here.
Keywords: her2; breast cancer; gpcrs; her2 breast ... See more keywords
NRF1 motif sequence-enriched genes involved in ER/PR −ve HER2 +ve breast cancer signaling pathways
Sign Up to like & getrecommendations! Published in 2018 at "Breast Cancer Research and Treatment"
DOI: 10.1007/s10549-018-4905-9
Abstract: Nuclear respiratory factor 1 (NRF1) transcription factor has recently been shown to control breast cancer progression. However, mechanistic aspects by which NRF1 may contribute to susceptibility to different breast tumor subtypes are still not fully… read more here.
Keywords: her2 breast; breast; breast cancer; nrf1 motif ... See more keywords
The prevalence of luminal B subtype is higher in older postmenopausal women with ER+/HER2- breast cancer and is associated with inferior outcomes.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of geriatric oncology"
DOI: 10.1016/j.jgo.2020.08.007
Abstract: OBJECTIVES To establish whether clinicopathologic and genomic characteristics may explain the poor prognosis associated with advanced age in ER+/HER2- breast cancer. MATERIALS AND METHODS The cohort included 271 consecutive post-menopausal patients with ER+/HER2- invasive breast… read more here.
Keywords: older patients; breast cancer; her2 breast; luminal subtype ... See more keywords
Discovery and Characterization of PVTX-321 as a Potent and Orally Bioavailable Estrogen Receptor Degrader for ER+/HER2- Breast Cancer.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of medicinal chemistry"
DOI: 10.1021/acs.jmedchem.5c00223
Abstract: Estrogen receptor α (ERα) is a key therapeutic target in ER+/HER2- breast cancer, but ESR1 mutations drive resistance to endocrine therapies. Heterobifunctional degraders (HBDs) targeting ERα offer a promising strategy to overcome this resistance. Here,… read more here.
Keywords: her2 breast; breast cancer; pvtx 321; estrogen receptor ... See more keywords
Melatonin potentiates the cytotoxic effect of Neratinib in HER2+ breast cancer through promoting endocytosis and lysosomal degradation of HER2
Sign Up to like & getrecommendations! Published in 2021 at "Oncogene"
DOI: 10.1038/s41388-021-02015-w
Abstract: Complete blockade of the HER2 protein itself and HER signaling network is critical to achieving effective HER2-targeted therapies. Despite the success of HER2-targeted therapies, the diseases will relapse in a significant fraction of patients with… read more here.
Keywords: her2 breast; breast cancer; effect; melatonin ... See more keywords
ZMYND8 drives HER2 antibody resistance in breast cancer via lipid control of IL-27
Sign Up to like & getrecommendations! Published in 2025 at "Nature Communications"
DOI: 10.1038/s41467-025-59184-5
Abstract: Anti-HER2 antibodies are effective but often lead to resistance in patients with HER2+ breast cancer. Here, we report an epigenetic crosstalk with aberrant glycerophospholipid metabolism and inflammation as a key resistance mechanism of anti-HER2 therapies… read more here.
Keywords: her2 breast; cancer; resistance; breast cancer ... See more keywords
Clinical development of immunotherapies for HER2+ breast cancer: a review of HER2-directed monoclonal antibodies and beyond
Sign Up to like & getrecommendations! Published in 2020 at "NPJ Breast Cancer"
DOI: 10.1038/s41523-020-0153-3
Abstract: Human epidermal growth factor receptor 2–positive (HER2+) breast cancer accounts for ~25% of breast cancer cases. Monoclonal antibodies (mAbs) against HER2 have led to unparalleled clinical benefit for a subset of patients with HER2+ breast… read more here.
Keywords: cancer; immunotherapies her2; her2 breast; breast cancer ... See more keywords
Clinical impact of single-gene vs. panel sequencing in advanced HR + /HER2− breast cancer: insights and implications
Sign Up to like & getrecommendations! Published in 2025 at "NPJ Breast Cancer"
DOI: 10.1038/s41523-025-00805-z
Abstract: Hormone receptor-positive (HR + )/HER2−negative (HER2 − ) breast cancer is the most common subtype, with biomarker-driven therapies improving outcomes. Circulating tumor DNA (ctDNA) analysis enables minimally invasive assessment of somatic alterations to guide therapy. However, assay choice impacts… read more here.
Keywords: her2 breast; her2; breast cancer; single gene ... See more keywords
MicroRNA in combination with HER2-targeting drugs reduces breast cancer cell viability in vitro
Sign Up to like & getrecommendations! Published in 2021 at "Scientific Reports"
DOI: 10.1038/s41598-021-90385-2
Abstract: HER2-positive (HER2 +) breast cancer patients that do not respond to targeted treatment have a poor prognosis. The effects of targeted treatment on endogenous microRNA (miRNA) expression levels are unclear. We report that responsive HER2 + breast cancer… read more here.
Keywords: her2 breast; mir; breast; breast cancer ... See more keywords